Genome & Company (KOSDAQ:314130)
South Korea
· Delayed Price · Currency is KRW 5,260.00
+810.00 (18.20%)
At close: Dec 5, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Immuno-cancer Drugs - Product | 13.36B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Immuno-cancer Drugs - Product Growth | 115.01% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Service | 7.29B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Service Growth | -7.26% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Usage Fee | 7.10B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Usage Fee Growth | 3251.04% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Immuno-cancer Drugs - Merchandise | 800.00K |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Immuno-cancer Drugs - Merchandise Growth | -94.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Products | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biological Products Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| North America | 9.60B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe | 7.37B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South Korea | 6.30B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South Korea Growth | -55.92% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia | 4.43B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South America | 29.46M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oceania | 10.97M |
Log In |
Log In |
Log In |
Log In | Upgrade
|